<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506064</url>
  </required_header>
  <id_info>
    <org_study_id>DM02-563</org_study_id>
    <nct_id>NCT00506064</nct_id>
  </id_info>
  <brief_title>Melatonin Postoperative Sleep Study in Breast Cancer Patients</brief_title>
  <official_title>Melatonin Postoperative Sleep Study in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the impact of postoperative exogenous nocturnal melatonin supplementation on the
      early regulation of the sleep-wake cycle and its clinical impact (subjective improvement of
      the quality of sleep and reduction of cardiopulmonary events) during the first postoperative
      week following anesthesia and surgery in older breast cancer patients receiving a unilateral
      segmental mastectomy with or without intraoperative lymph node mapping, sentinel node biopsy
      and axillary node dissection.

      Secondary Objective:

      To collect data and validate the Postoperative Srejic Sleep SAT Survey Questionnaire (SAT
      implies relative subjective satisfaction of the patient's sleep in a scaled score out of 100
      with 100 being the highest degree of satisfaction).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melatonin is produced by a small gland in the brain called the pineal gland. During times of
      stress, use of certain medications, and increasing age, melatonin production may be disrupted
      or weakened. This may cause sleep disturbance. Many of the drugs used for pain, anesthesia,
      or cancer treatment may affect the body's natural secretion of melatonin.

      Participants in this study will be randomly assigned (as in the toss of a coin) to one of two
      treatment groups. Participants in one group will receive melatonin. Participants in the other
      group will receive a placebo. A placebo is a substance that looks like the study drug, but
      which has no active ingredients. There is an equal chance of being in either group. Neither
      you nor the study doctor will know to which group you are assigned. You will take either two,
      three, or four capsules 30 minutes before you go to bed. You will go to bed at about the same
      time each day (around 10:00PM). The number of capsules will be prescribed according to your
      body weight.

      Researchers will attach two monitors to you while you are sleeping to test for changes during
      sleep. An actigraph wrist monitor will be worn on the non-dominant wrist (to measure sleep
      movement and patterns). A pulse oximeter will be worn on the opposite hand/finger (to measure
      the amount of oxygen in the blood). You may use these devices as an inpatient or outpatient
      at home.

      Each day of the study (for one week after the operation and anesthesia) you will fill out 1-2
      questionnaires depending on the day. The researchers will ask questions about your last
      night's sleep and how you are feeling. The questionnaires will be filled out each evening.
      This will take less than 10 minutes.

      If on Day 4 you require any additional sleep medicine or have been experiencing any
      unpleasant side effects of melatonin, you may remove yourself from the study. The entire
      length of this study is made up of the one week after your surgery. Should you take any other
      sleep aids during the time of the study, please tell the research staff as your questionnaire
      data cannot then be used for this study.

      You will visit your cancer doctor and the study doctor at least one time after your surgery.
      This follow-up visit will be coordinated with your surgical postoperative visit. Researchers
      may go over some parts of the questionnaires and retrieve the actigraph and pulse oximeter
      from you.

      This is an investigational study. Melatonin has not gone through the FDA approval process.
      However, melatonin supplements are commercially available in over-the-counter form. Forty
      patients will take part in this study. All will be enrolled at UTMDACC.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to low accrual.
  </why_stopped>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Sleep Response of Patients</measure>
    <time_frame>Longitudinal study with major responses measured on days 0 (day of operation) and days 1-6 post-operative</time_frame>
    <description>Objective responses measured by wrist actigraph (measures sleep movement), and the Sp02 monitor (measures the % oxy-hemoglobin in the blood)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15 mg/kg capsules by mouth daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Starch capsules by mouth daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>0.15 mg/kg by mouth (PO) Daily</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two, three, or four starch tablet or capsules before bed</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Sleep study surveys, two per day completed each evening, lasting 10 minutes</description>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Survey</other_name>
    <other_name>Insomnia Syndrome Questionnaire</other_name>
    <other_name>Postoperative Srejic Sleep SAT Survey Questionnaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Breast cancer patients having a unilateral segmental mastectomy, with or without
             intraoperative lymph node mapping, sentinel node biopsy, and axillary node dissection

          2. Ages &gt;= 40 years

          3. American Society of Anesthesiology (ASA) physical status classification of
             preoperative functioning) 1-4 levels are acceptable

          4. Willing and able to give written informed consent

          5. Willing and able to complete questionnaires

          6. Not currently taking benzodiazepine medication for insomnia.

        Exclusion Criteria:

          1. Autoimmune diseases: rheumatoid arthritis, systemic lupus, or other collagen vascular
             disease

          2. Alcoholics

          3. Seizure disorder

          4. Thyroid disease

          5. Pregnant or lactating patients (effects not known in pregnancy)

          6. Renal/hepatic failure (if ood urea nitrogen (BUN) or creatinine (Cr) &gt;2.5* Upper limit
             of normal (ULN); Bili or aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT)&gt;2.5* ULN)

          7. Dementia/poor compliance

          8. Manic/psychotic patients

          9. Children/adults under 40 yrs

         10. Movement disorders (ex. restless leg syndrome)

         11. Tremor disorder (ex. parkinsonism)

         12. Chronic benzodiazepine use for sleep (&gt;4 times per week )

         13. Designated preop medications including melatonin for sleep
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Una Srejic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2007</study_first_submitted>
  <study_first_submitted_qc>July 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>March 29, 2010</results_first_submitted>
  <results_first_submitted_qc>December 28, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2011</results_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Sleep</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Survey</keyword>
  <keyword>Postoperative Srejic Sleep SAT Survey</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 01/26/07 through 10/10/07. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Protocol terminated early as unable to accrue cases. There were four patients accrued of which three were not assigned, therefore data available for only one case.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Melatonin</title>
          <description>0.15 mg/kg capsules by mouth daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Starch capsules by mouth daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melatonin</title>
          <description>0.15 mg/kg capsules by mouth daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Starch capsules by mouth daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="49" upper_limit="49"/>
                    <measurement group_id="B3" value="1" lower_limit="49" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Sleep Response of Patients</title>
        <description>Objective responses measured by wrist actigraph (measures sleep movement), and the Sp02 monitor (measures the % oxy-hemoglobin in the blood)</description>
        <time_frame>Longitudinal study with major responses measured on days 0 (day of operation) and days 1-6 post-operative</time_frame>
        <population>Since unable to accrue an adequate number of cases with data, unable to provide analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>0.15 mg/kg capsules by mouth daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Starch capsules by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Sleep Response of Patients</title>
          <description>Objective responses measured by wrist actigraph (measures sleep movement), and the Sp02 monitor (measures the % oxy-hemoglobin in the blood)</description>
          <population>Since unable to accrue an adequate number of cases with data, unable to provide analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Melatonin</title>
          <description>0.15 mg/kg capsules by mouth daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Starch capsules by mouth daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated early due to low recruitment, no analysis done.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Una Srejic, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-6914</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

